| Yasir Ali Alzubaidi, MD | |
|
424 S 56th St Ste 110, Phoenix, AZ 85034-2177 | |
| (602) 685-5211 | |
| (480) 478-8095 |
| Full Name | Yasir Ali Alzubaidi |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 20 Years |
| Location | 424 S 56th St Ste 110, Phoenix, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962867887 | NPI | - | NPPES |
| 1962867887 | Medicaid | MI |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chandler Regional Medical Center | Chandler, AZ | Hospital |
| Mercy Gilbert Medical Center | Gilbert, AZ | Hospital |
| Summit Healthcare Regional Medical Center | Show low, AZ | Hospital |
| Mountain Vista Medical Center, Lp | Mesa, AZ | Hospital |
| Abrazo West Campus | Goodyear, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pathology Specialist Of Arizona, Llp | 4789583188 | 61 |
| Clin-path Pathology | 5193717866 | 32 |
News Archive
Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in HER2+ breast cancer patients.
Emergent BioSolutions Inc.today hosted "Looking Beyond the Bench," a symposium organized for doctoral students enrolled in the NIH-Oxford-Cambridge Scholars Program. The symposium featured Emergent executives, who, based industry, provided insight on potential career paths awaiting biomedical researchers.
Jersey Shore University Medical Center hosted a roundtable discussion on August 4, led by Assemblywoman Mary Pat Angelini, to discuss the continued growth in heroin and prescription drug abuse in the shore community.
The reality of existing insurance coverage precludes effective implementation of four newly released cardiovascular guidelines from the American Heart Association and American College of Cardiology, according to the Academy of Nutrition and Dietetics. The Academy supports the new guidelines and urges public and private insurance carriers to follow the recommendations so that Americans will have access to health care they deserve.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.
› Verified 9 days ago
| Entity Name | Pathology Specialist Of Arizona, Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174503999 PECOS PAC ID: 4789583188 Enrollment ID: O20040105000801 |
News Archive
Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in HER2+ breast cancer patients.
Emergent BioSolutions Inc.today hosted "Looking Beyond the Bench," a symposium organized for doctoral students enrolled in the NIH-Oxford-Cambridge Scholars Program. The symposium featured Emergent executives, who, based industry, provided insight on potential career paths awaiting biomedical researchers.
Jersey Shore University Medical Center hosted a roundtable discussion on August 4, led by Assemblywoman Mary Pat Angelini, to discuss the continued growth in heroin and prescription drug abuse in the shore community.
The reality of existing insurance coverage precludes effective implementation of four newly released cardiovascular guidelines from the American Heart Association and American College of Cardiology, according to the Academy of Nutrition and Dietetics. The Academy supports the new guidelines and urges public and private insurance carriers to follow the recommendations so that Americans will have access to health care they deserve.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.
› Verified 9 days ago
| Entity Name | Clin-path Pathology |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922079706 PECOS PAC ID: 5193717866 Enrollment ID: O20040401000920 |
News Archive
Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in HER2+ breast cancer patients.
Emergent BioSolutions Inc.today hosted "Looking Beyond the Bench," a symposium organized for doctoral students enrolled in the NIH-Oxford-Cambridge Scholars Program. The symposium featured Emergent executives, who, based industry, provided insight on potential career paths awaiting biomedical researchers.
Jersey Shore University Medical Center hosted a roundtable discussion on August 4, led by Assemblywoman Mary Pat Angelini, to discuss the continued growth in heroin and prescription drug abuse in the shore community.
The reality of existing insurance coverage precludes effective implementation of four newly released cardiovascular guidelines from the American Heart Association and American College of Cardiology, according to the Academy of Nutrition and Dietetics. The Academy supports the new guidelines and urges public and private insurance carriers to follow the recommendations so that Americans will have access to health care they deserve.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Yasir Ali Alzubaidi, MD 3490 Calkins Rd, Flint, MI 48532-3506 Ph: (810) 733-7741 | Yasir Ali Alzubaidi, MD 424 S 56th St Ste 110, Phoenix, AZ 85034-2177 Ph: (602) 685-5211 |
News Archive
Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in HER2+ breast cancer patients.
Emergent BioSolutions Inc.today hosted "Looking Beyond the Bench," a symposium organized for doctoral students enrolled in the NIH-Oxford-Cambridge Scholars Program. The symposium featured Emergent executives, who, based industry, provided insight on potential career paths awaiting biomedical researchers.
Jersey Shore University Medical Center hosted a roundtable discussion on August 4, led by Assemblywoman Mary Pat Angelini, to discuss the continued growth in heroin and prescription drug abuse in the shore community.
The reality of existing insurance coverage precludes effective implementation of four newly released cardiovascular guidelines from the American Heart Association and American College of Cardiology, according to the Academy of Nutrition and Dietetics. The Academy supports the new guidelines and urges public and private insurance carriers to follow the recommendations so that Americans will have access to health care they deserve.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.
› Verified 9 days ago
Dr. Natasha Elizabeth Lewis, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 5777 E Mayo Blvd, Phoenix, AZ 85054 Phone: 480-301-8000 | |
Dr. Nasma Kamil Majeed, MD Pathology Medicare: Medicare Enrolled Practice Location: 1111 E Mcdowell Rd, Phoenix, AZ 85006 Phone: 602-685-5211 Fax: 623-322-4639 | |
David J Glembocki, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 11130 N Tatum Blvd, Suite 100, Phoenix, AZ 85028 Phone: 602-494-1817 Fax: 602-494-7103 | |
Suzan Kavusi, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 650 E Indian School Rd, Phoenix, AZ 85012 Phone: 602-277-5551 | |
Dr. Maria P Alzona, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 424 S 56th St Ste 120, Phoenix, AZ 85034 Phone: 602-685-5211 Fax: 602-685-5325 | |
Anna Marie Felty-duckworth, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 650 E Indian School Rd, Cs/113, Phoenix, AZ 85012 Phone: 602-277-5551 Fax: 602-222-2669 | |
Renuka Pathi, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 22216 N 36th St, Phoenix, AZ 85050 Phone: 602-606-7375 |